# Scion Life Sciences

Scion Life Sciences is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** 220 East 42nd Street, 37th / PH Floor, New York, NY 10017, United States
- **Founded:** 2024
- **Assets under management:** $310 million (per firm press release, February 2024)
- **Website:** scionlifesciences.com
- **LinkedIn:** https://www.linkedin.com/company/scion-life-sciences

## Regulatory record

- **Reports private funds:** No

## About

We are dedicated to making medicines that cure or transform the clinical management of serious and life-threatening diseases. We create and build exceptional companies with this singular goal in mind and nurture them through to maturity and realization of the full potential of their therapeutic innovations.

## Sectors

- Biotechnology
- Healthcare Services

## People

- Samuel Hall, PhD — Managing Partner
- Aaron Kantoff — Managing Partner
- Tadd Wessel — Managing Partner

## Questions

### Who runs investment decisions at Scion Life Sciences?

The three managing partners — Samuel Hall, Aaron Kantoff, and Tadd Wessel — lead investment decisions. All three were involved in founding the firm in 2024, and the partnership structure consolidates authority within this small group rather than dispersing it across a large investment committee.

### How does Scion Life Sciences source proprietary deal flow?

Scion generates most of its deal flow internally by conceiving therapeutic ideas in-house and then building companies around them. The firm also sources innovations through direct academic and industry partnerships, but it primarily acts as a founder rather than a screener of externally pitched startups.

### Is Scion structured as a traditional venture fund or something different?

Scion operates more like a biotech company-creation studio than a conventional venture capital firm. It founds and builds companies from scratch, often starting with a therapeutic concept on paper, and stays involved through late-stage clinical development and commercialization rather than entering at a defined Series A round.

### What investment stages does Scion target?

Scion invests from inception — described as 'mere ideas on napkins' — through to late-stage clinical trials and commercialization. The firm does not restrict itself to a specific stage window and will continue to fund a portfolio company across multiple rounds as long as the therapeutic program justifies further capital.

### Does Scion Life Sciences maintain partnerships with external academic groups?

Yes. The firm actively solicits ideas from academic labs and industry partners. Its contact page invites researchers with a project to reach out, and the firm integrates externally sourced therapeutic innovations into its company-creation pipeline alongside internally conceived programs.

### What does the April 2025 venture-partner expansion signal about Scion's direction?

Adding Lalo Flores, Huw Nash, and Romesh Subramanian as venture partners broadens Scion's scientific expertise and its capacity to incubate multiple companies simultaneously. The appointments suggest the firm is scaling its founding model while keeping the core managing-partner group small.

## Related profiles

- [SciFounders](https://altss.com/profile/scifounders)
- [Scissortail Wealth Management](https://altss.com/profile/scissortail-wealth-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/scion-life-sciences

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology